S&P 500   3,324.42 (+0.23%)
DOW   29,316.18 (+0.06%)
QQQ   222.76 (+0.22%)
AAPL   316.27 (+0.33%)
FB   221.62 (-0.07%)
MSFT   166.33 (+0.10%)
GOOGL   1,465.18 (+1.04%)
AMZN   1,865.63 (-0.66%)
CGC   24.90 (+2.47%)
NVDA   248.38 (-0.22%)
BABA   226.45 (+1.12%)
MU   57.62 (-0.10%)
GE   11.81 (-0.34%)
TSLA   506.97 (-1.27%)
AMD   50.78 (+2.03%)
T   38.33 (+0.79%)
ACB   2.10 (-2.33%)
F   9.17 (-0.11%)
NFLX   338.49 (-0.04%)
PRI   128.78 (+0.32%)
BAC   34.64 (-0.23%)
DIS   144.72 (-0.28%)
S&P 500   3,324.42 (+0.23%)
DOW   29,316.18 (+0.06%)
QQQ   222.76 (+0.22%)
AAPL   316.27 (+0.33%)
FB   221.62 (-0.07%)
MSFT   166.33 (+0.10%)
GOOGL   1,465.18 (+1.04%)
AMZN   1,865.63 (-0.66%)
CGC   24.90 (+2.47%)
NVDA   248.38 (-0.22%)
BABA   226.45 (+1.12%)
MU   57.62 (-0.10%)
GE   11.81 (-0.34%)
TSLA   506.97 (-1.27%)
AMD   50.78 (+2.03%)
T   38.33 (+0.79%)
ACB   2.10 (-2.33%)
F   9.17 (-0.11%)
NFLX   338.49 (-0.04%)
PRI   128.78 (+0.32%)
BAC   34.64 (-0.23%)
DIS   144.72 (-0.28%)
S&P 500   3,324.42 (+0.23%)
DOW   29,316.18 (+0.06%)
QQQ   222.76 (+0.22%)
AAPL   316.27 (+0.33%)
FB   221.62 (-0.07%)
MSFT   166.33 (+0.10%)
GOOGL   1,465.18 (+1.04%)
AMZN   1,865.63 (-0.66%)
CGC   24.90 (+2.47%)
NVDA   248.38 (-0.22%)
BABA   226.45 (+1.12%)
MU   57.62 (-0.10%)
GE   11.81 (-0.34%)
TSLA   506.97 (-1.27%)
AMD   50.78 (+2.03%)
T   38.33 (+0.79%)
ACB   2.10 (-2.33%)
F   9.17 (-0.11%)
NFLX   338.49 (-0.04%)
PRI   128.78 (+0.32%)
BAC   34.64 (-0.23%)
DIS   144.72 (-0.28%)
S&P 500   3,324.42 (+0.23%)
DOW   29,316.18 (+0.06%)
QQQ   222.76 (+0.22%)
AAPL   316.27 (+0.33%)
FB   221.62 (-0.07%)
MSFT   166.33 (+0.10%)
GOOGL   1,465.18 (+1.04%)
AMZN   1,865.63 (-0.66%)
CGC   24.90 (+2.47%)
NVDA   248.38 (-0.22%)
BABA   226.45 (+1.12%)
MU   57.62 (-0.10%)
GE   11.81 (-0.34%)
TSLA   506.97 (-1.27%)
AMD   50.78 (+2.03%)
T   38.33 (+0.79%)
ACB   2.10 (-2.33%)
F   9.17 (-0.11%)
NFLX   338.49 (-0.04%)
PRI   128.78 (+0.32%)
BAC   34.64 (-0.23%)
DIS   144.72 (-0.28%)
Log in

NASDAQ:KLDO - Kaleido Biosciences Stock Price, Forecast & News

$5.03
-0.07 (-1.37 %)
(As of 01/17/2020 01:27 PM ET)
Today's Range
$5.03
Now: $5.03
$5.19
50-Day Range
$4.95
MA: $5.89
$8.83
52-Week Range
$4.61
Now: $5.03
$19.00
Volume4,528 shs
Average Volume125,932 shs
Market Capitalization$151.22 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KLDO
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees118
Market Cap$151.22 million
Next Earnings Date1/29/2020 (Estimated)
OptionableNot Optionable

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.


Breaking News: Marijuana legislation is great news for marijuana investors (Ad)


A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences Inc (NASDAQ:KLDO) issued its earnings results on Wednesday, October, 30th. The company reported ($0.74) EPS for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.15. View Kaleido Biosciences' Earnings History.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Kaleido Biosciences.

What price target have analysts set for KLDO?

5 equities research analysts have issued 12-month price objectives for Kaleido Biosciences' shares. Their forecasts range from $15.00 to $20.00. On average, they expect Kaleido Biosciences' share price to reach $17.70 in the next twelve months. This suggests a possible upside of 251.9% from the stock's current price. View Analyst Price Targets for Kaleido Biosciences.

What is the consensus analysts' recommendation for Kaleido Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kaleido Biosciences.

Has Kaleido Biosciences been receiving favorable news coverage?

Headlines about KLDO stock have trended very negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kaleido Biosciences earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Kaleido Biosciences.

Are investors shorting Kaleido Biosciences?

Kaleido Biosciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,820,000 shares, an increase of 20.5% from the December 15th total of 1,510,000 shares. Based on an average daily trading volume, of 123,900 shares, the short-interest ratio is presently 14.7 days. Currently, 20.2% of the shares of the company are short sold. View Kaleido Biosciences' Current Options Chain.

Who are some of Kaleido Biosciences' key competitors?

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Precision BioSciences (DTIL), Gossamer Bio (GOSS), LogicBio Therapeutics (LOGC), Exxon Mobil (XOM), NVIDIA (NVDA), Pfizer (PFE), Akero Therapeutics (AKRO) and Micron Technology (MU).

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the folowing people:
  • Mr. Michael W. Bonney, Exec. Chair (Age 61)
  • Ms. Alison Lawton, CEO, Pres & Director (Age 58)
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder & Director (Age 56)
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 38)
  • Mr. Joshua T. Brumm, COO & CFO (Age 41)

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $5.03.

How big of a company is Kaleido Biosciences?

Kaleido Biosciences has a market capitalization of $151.22 million. Kaleido Biosciences employs 118 workers across the globe.View Additional Information About Kaleido Biosciences.


MarketBeat Community Rating for Kaleido Biosciences (NASDAQ KLDO)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  78
MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote "Outperform" if you believe KLDO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Range Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel